Clinical Scorecard: Managing Neurotrophic Keratitis

At a Glance

Key Highlights

• Early identification of NK is crucial to prevent complications such as scarring and vision loss.
• The condition is classified into three stages based on corneal damage severity.
• Management strategies include preservative-free lubrication, immunomodulators, and potential surgical interventions.
• Corneal sensitivity testing is essential for diagnosis and monitoring.
• Recombinant human nerve growth factor (rhNGF) is FDA approved for stages 2 to 3 NK.
• Corneal sensitivity testing is critical for diagnosis.

Guideline-Based Recommendations

Diagnosis

• Perform slit lamp examination and corneal sensitivity testing.
• Utilize vital stains and Schirmer test to evaluate ocular surface integrity.
• Consider additional examinations such as in vivo confocal microscopy.

Management

• Use preservative-free lubrication and consider punctal occlusion for tear retention.
• Initiate topical antibiotics if persistent epithelial defects are present.
• Consider rhNGF or cryopreserved amniotic membrane for nonresponsive stage 1 patients.

Monitoring & Follow-up

• Schedule follow-up appointments based on disease severity and response to treatment.
• Monitor for complications such as hypoxia or microbial risk with bandage contact lenses.

Risks

• Delayed recognition can lead to persistent epithelial defects, stromal melt, and vision loss.
• Patients with a history of severe dry eye disease are at increased risk for developing NK.

Patient & Prescribing Data

Optimal healing may require multiple staged interventions and patient education on the chronic nature of the condition, emphasizing the importance of adherence to treatment.

Clinical Best Practices

• Incorporate corneal sensitivity testing into initial evaluations.
• Frame NK as a chronic condition to enhance patient compliance with treatment.
• Utilize a combination of therapies tailored to the stage of NK.

Related Resources & Content

• Managing Neurotrophic Keratitis